73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1CHICAGO, June 3, 2024
https://www.cnbc.com/2024/06/03/microsoft-confirms-mixed-reality-layoffs-will-keep-selling-hololens-2.html#:~:text=Microsoft%20will%20lay%20off%20some,first%20became%20available%20in%202019.Microsoft will lay off some
88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and